TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • February 28, 2019

SILVER SPRING, MD—The FDA approved a label expansion for Sprycel (dasatinib) as a treatment for pediatric patients age one and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy. Sprycel is the only second-generation tyrosine kinase inhibitor approved as a treatment for this patient population. It is manufactured by Bristol-Myers Squibb, New York, NY.